Lilly Will Play The Metabolism Card In Effient's Imminent U.S. Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Meanwhile, second-quarter sales of the oral platelet inhibitor outside the U.S. prove to be…thin.
You may also be interested in...
Medco "Genetics For Generics" Research Anticipates Plavix Patent Loss
Medco is working to generate cost effectiveness data for Bristol-Myers Squibb's anti-clotting blockbuster Plavix in anticipation of the launch of clopidogrel generics in 2011
Medco "Genetics For Generics" Research Anticipates Plavix Patent Loss
Medco is working to generate cost effectiveness data for Bristol-Myers Squibb's anti-clotting blockbuster Plavix in anticipation of the launch of clopidogrel generics in 2011
Plavix Pharmacogenomic Label Update May Help Lilly With Effient Launch
When Lilly's Effient (prasugrel) finally cleared FDA July 10, the first thing everyone noticed is the "black box" warning of a potential increased risk of bleeding associated with the antithrombotic drug